文献速递生殖医学

IVM与IVF出生儿童的发育比较:一项随机对照试验的2年随访

Development of children born from IVM versus IVF: 2-year follow-up of a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2022-01-01

本研究对参与比较CAPA IVM与常规IVF的随机对照试验的231名儿童进行24个月发育随访,发现IVM与IVF出生儿童在6、12、24月龄的ASQ-3总分无显著差异,发育预警比例低且两组无差异;双胎中IVM组6月龄问题解决和个人-社交评分略低但仍在正常范围,12和24月龄时已赶上IVF组。

要点

  • IVM与IVF出生儿童在24个月内的总体发育相当。
  • 双胎中IVM组6月龄ASQ-3问题解决和个人-社交评分略低于IVF组,但12和24月龄时已赶上。
  • 确诊精神和/或运动发育异常的儿童:IVM组4例 vs IVF组2例,相对风险2.91(95%CI 0.54-15.6;P=0.23),无显著差异。

核心结论

  • 基于目前2年随访的发现,似乎没有关于IVM对儿童发育影响的显著担忧。
  • 这些数据为医生考虑不同生育治疗方法时增加了可用证据,但需要在更大规模的研究中验证。

研究设计与样本

  • 本研究是对参与比较IVM(含预成熟步骤,CAPA IVM)与IVF的随机对照试验的妇女所生婴儿的随访。
  • 共对231名儿童进行了24个月随访的发育评估。
  • 随机对照试验的参与者有ART指征且窦卵泡计数高(双侧卵巢卵泡≥24个),随机接受一个周期的IVM(n=273)或IVF(n=273)。
  • 其中分别有96名和118名妇女获得活产。
  • 分别有76名妇女(94名儿童,79.2%)和104名妇女(137名儿童,88.1%)完成了年龄与发育进程问卷第三版(ASQ-3)评估,并在6、12和24月龄时接受了发育预警评估。

主要发现

  • 随访研究中IVM组和IVF组参与者的基线特征相当。
  • 总体而言,IVM或IVF出生儿童在6、12和24月龄时的ASQ-3评分无显著差异。
  • 存在发育预警的儿童比例低,且两组间无差异。
  • 双胎中IVM组与IVF组相比,6月龄时ASQ-3问题解决和个人-社交评分略低但显著,仍在正常范围内,并在12和24月龄评估时赶上IVF组。
  • 经专科评估确诊精神和/或运动发育异常的儿童数:IVM组4例,IVF组2例(相对风险2.91,95%CI 0.54-15.6;P=0.23)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究是一项开放标签的随机对照试验参与者随访,并非所有原始试验对象都参与了随访。
  • 随访人群的自我选择性质可能引入偏倚,且样本量可能不足以检测发育结局的显著组间差异。
  • 这些数据需要在更大规模的研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there any difference in developmental outcomes in children born after capacitation IVM (CAPA IVM) compared with conventional IVF? SUMMARY ANSWER: Overall development up to 24 months of age was comparable in children born after CAPA IVM compared with IVF. WHAT IS KNOWN ALREADY: IVM has been shown to be a feasible alternative to conventional IVF in women with a high antral follicle count (AFC). In addition to live birth rate, childhood development is also a relevant metric to compare between the two approaches to ART and there are currently no data on this. STUDY DESIGN, SIZE, DURATION: This study was a follow-up of babies born to women who participated in a randomized controlled trial comparing IVM with a pre-maturation step (CAPA IVM) and IVF. Developmental assessments were performed on 231 children over 24 months of follow-up. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants in the randomized controlled trial had an indication for ART and a high AFC (≥24 follicles in both ovaries). They were randomized to undergo one cycle of either IVM (n = 273) or IVF (n = 273). Of these, 96 women and 118 women, respectively, had live births. Seventy-six women (94 children, 79.2%) and 104 women (137 children, 88.1%), respectively, completed Ages & Stages Third Edition Questionnaire assessment (ASQ-3), and underwent evaluation of Developmental Red Flags at 6, 12 and 24 months of age. MAIN RESULTS AND THE ROLE OF CHANCE: Baseline characteristics of participants in the follow-up study between the IVM and IVF groups were comparable. Overall, there were no significant differences in ASQ-3 scores at 6, 12 and 24 months between children born after IVM or IVF. The proportion of children with developmental red flags was low and did not differ between the two groups. Slightly, but significantly, lower ASQ-3 problem solving and personal-social scores in twins from the IVM versus IVF group at 6 months were still within the normal range and had caught up to the IVF group in the 12- and 24-month assessments. The number of children confirmed to have abnormal mental and/or motor development after specialist assessment was four in the IVM group and two in the IVF group (relative risk 2.91, 95% CI 0.54-15.6; P = 0.23). LIMITATIONS, REASONS FOR CAUTION: This study is an open-label follow-up of participants in a randomized controlled trial, and not all original trial subjects took part in the follow-up. The self-selected nature of the follow-up population could have introduced bias, and the sample size may have been insufficient to detect significant between-group differences in developmental outcomes. WIDER IMPLICATIONS OF THE FINDINGS: Based on the current findings at 2 years of follow-up, there does not appear to be any significant concern about the effects of IVM on childhood development. These data add to the evidence available to physicians when considering different approaches to fertility treatment, but require validation in larger studies. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number FWO.106-YS.2017.02. L.N.V. has received speaker and conference fees from Merck, grant, speaker and conference fees from Merck Sharpe and Dohme, and speaker, conference and scientific board fees from Ferring; T.M.H. has received speaker fees from Merck, Merck Sharp and Dohme, and Ferring; R.J.N. has receives grant funding from the National Health and Medical Research Council (NHMRC) of Australia; B.W.M. has acted as a paid consultant to Merck, ObsEva and Guerbet and is the recipient of grant money from an NHMRC Investigator Grant; J.E.J.S. reports lecture fees from Ferring Pharmaceuticals, Biomérieux and Besins Female Healthcare, grants from Fund for Research Flanders (FWO) and is co-inventor on granted patents on CAPA-IVM methodology in the USA (US10392601B2) and Europe (EP3234112B1); T.D.P., M.H.N.N., N.A.N., T.T.L., V.T.T.T., N.T.N., H.L.T.H. and X.T.H.L. have no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work. TRIAL REGISTRATION NUMBER: NCT04296357 (www.clinicaltrials.gov). TRIAL REGISTRATION DATE: 5 March 2020. DATE OF FIRST PATIENT’S ENROLMENT: 7 March 2020.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Vuong LN, Nguyen MHN, Nguyen NA, et al. Development of children born from IVM versus IVF: 2-year follow-up of a randomized controlled trial. Hum Reprod. 2022. PMID: 35595193. doi:10.1093/humrep/deac115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。